From the Division of Endocrinology, Diabetes, and Hypertension (Y.T., V.C., A.R.C., C.J.L., W.W., F.B., D.B., E.C., R.K.T., R.E.L., W.A.H.) and the Department of Pathology (M.C.F.), David Geffen School of Medicine, University of California, Los Angeles; Second Department of Internal Medicine (Y.T., J.H.), Ehime University School of Medicine, Japan; Division of Endocrinology and Molecular Medicine (D.B.), University of Kentucky College of Medicine, Lexington; Novartis Pharmaceuticals Corporation (W.D... (At 2005-10-28)